Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v6-EN | Version v6-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2020-05-02 | 2020-05-02 |
| Drug Identification Number | 00761850 | 00761850 |
| Brand name | DOPAMINE HCL 0.8MG/ML DEXTROSE 5% INJ USP | DOPAMINE HCL 0.8MG/ML DEXTROSE 5% INJ USP |
| Common or Proper name | Dopamine | Dopamine |
| Company Name | BAXTER CORPORATION | BAXTER CORPORATION |
| Ingredients | DOPAMINE HYDROCHLORIDE DEXTROSE | DOPAMINE HYDROCHLORIDE DEXTROSE |
| Strength(s) | .8MG 50MG | .8MG 50MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 250mL | 250mL |
| ATC code | C01CA | C01CA |
| ATC description | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | 2020-04-06 | 2020-04-06 |
| Actual start date | 2020-04-06 | 2020-04-06 |
| Estimated end date | 2020-05-01 | 2020-05-01 |
| Actual end date | 2020-05-01 | 2020-05-01 |
| Shortage status | Resolved | Resolved |
| Tier 3 Status | No | No |
| Company comments | Baxter products Dopamine Hydrochloride and 5% Dextrose USP – 400mg/250mL bags (DIN 00761826) and 800mg/250mL bags (DIN 00761834) are available as alternatives if they align with clinical practice. | Baxter products Dopamine Hydrochloride and 5% Dextrose USP – 400mg/250mL bags (DIN 00761826) and 800mg/250mL bags (DIN 00761834) are available as alternatives if they align with clinical practice. |
| Health Canada comments |